loading page

Pimavanserin: A life saviour for Parkinson’s Psychosis patients
  • Aashish Aashish,
  • Govinda Khatri
Aashish Aashish
Dow University of Health Sciences
Author Profile
Govinda Khatri
Dow University of Health Sciences
Author Profile

Abstract

Parkinson’s psychosis refers to psychotic symptoms such as illusions, hallucinations, and delusions that are frequently referred to as ‘positive,’ meaning a benefit. Quetiapine was the most commonly used initial atypical antipsychotic medicine for therapy, followed by Risperidone, Olanzapine, Aripiprazole, and other atypical antipsychotics. According to new research, Pimavanserin may surpass other therapy for older people with Parkinson’s disease (PD) psychosis. Pimavanserin is a powerful inverse agonist with a preference for 5-HT2A receptors over 5-HT2C receptors and no functional activity at a number of G-Protein coupled receptors GPRCs such as dopaminergic, muscarinic, adrenergic, and histaminergic receptors. Pimavanserin had a relative protective effect in 85 percent of the study group of PD patients living in the community.